Atherosclerosis Ischemia
Conditions
Interventions
treatment with either dipyridamole slow release 200 mg twice daily or no
treatment during 7 days with subsequent 4 week follow-up after cessation of the
treatment.
Sponsors
Pharmacology-Toxicology
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers Age 18-50 Written informed consent
Exclusion criteria
Exclusion criteria: Smoking History of any cardiovascular disease Asthma Hypertension (in supine position: systole>140 mm Hg, diastole>90 mmHg) Diabetes mellitus (fasting glucose >7.0 mmol/L or random glucose>11.0 mmol/L) Concomitant use of medication Alcohol or drug abuse Women without appropriate anticonception Participation to any drug-investigation during the previous 60 days as checked with VIP check
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of nucleoside uptake inhibition before, during (day 7), and after (day 14, 21, 28, and 35) treatment with dipyridamole between actively treated an control individuals at 35 days after start of the study (28 days after cessation of treatment in actively treated subjects). | — |
Secondary
| Measure | Time frame |
|---|---|
| plasma and whole blood dipyridamole concentration | — |
Countries
Netherlands
Outcome results
None listed